Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


极光加速器v3.0.7

July 31, 2025 - Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results July 7, 2025 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2025 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

极光加速器v3.0.7

极光加速器v3.0.7

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

极光加速器v3.0.7

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR
国外代理服务器ip免费  下载京东猫 加速器  布丁网络加速介绍  heroku搭建v2ray  佛跳加速器永久免费版下载  极速加速下载  安卓浏览器浏览国外